ArticleScientific reports2025
A lipid metabolism-related gene signature for risk stratification and prognosis prediction in patients with breast cancer.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer (BC) is among the cancers with the highest incidence rates. Although multiple therapies are available, there is an unmet need for prediction of prognoses and treatment responses. Increasing evidence has shown that lipid metabolism is important for the development of BC. The tumor-promoting role of lipid metabolism in BC has inspired us to build a model to predict prognosis and stratify patients using lipid metabolism-related genes (LMRGs) that may reflect the underlying biological mechanisms of BC. We identified a list of genes involved in lipid metabolism that were associated with the overall survival of BC. The above genes were selected by the least absolute shrinkage and selection operator (LASSO) method to avoid overfitting, and the stepwise Cox proportional hazards regression model was applied. The BC cohort of the Cancer Genome Atlas was divided into a training cohort and a test cohort at a ratio of 1:1. A six-gene signature, comprising APOC3, CEL, CPT1A, JAK2, NFKBIA, and PLA2G1B, was developed using the training cohort. There was a clear distinction in overall survival between low- and high-risk patients in the training cohort, the test cohort, various validation cohorts, and different clinical subgroups. Then, immune cell infiltration analysis, GO and KEGG analyses were performed. Enrichment analyses were applied to explore the possible underlying mechanisms. We also analyzed the susceptibility of patients to predefined drugs in different risk groups in an attempt to identify potential therapeutic drugs. Carnitine palmitoyl transferase 1A (CPT1A), one of the signature genes, is a key enzyme in lipid metabolism that has been related to cancer progression. Therefore, we analyzed the prognostic values of CPT1A in public cohorts and our independent BC cohort by performing immunohistochemistry. CPT1A was significantly related to overall survival in patients with BC in the cohorts. In general, the LMRG signature can predict overall survival and potential immunotherapy response in patients with BC, including triple-negative BC. The findings have highlighted the role of lipid metabolism and CPT1A in BC, showing the implications for further research, and the signature is a potential tool for prognosis prediction and may help clinicians with clinical decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.